Independent research on the U.S. markets, Baptista Research

Baptista Research

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. 

We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>ResMed, a global leader in connected health technology primarily focused on sleep and respiratory care, reported its fourth quarter and full fiscal year 2026 results, highlighting 9% and 10% headline revenue growth respectively, with 8% growth on a constant currency basis.</li><li>Non-GAAP earnings per share increased 16% in the quarter and 17% for the year, driven by operational efficiencies and margin expansion despite inflationary pressures.</li><li>The company generated $1.6 billion in free cash flow for fiscal 2026, supporting substantial shareholder returns through over $1 billion in combined share repurchases and dividends, with a notable 72% year-over-year increase in capital returned.</li></ul>

ResMed, a global leader in connected health technology primarily focused on sleep and respiratory care, reported its fourth quarter and full fiscal year 2026 results, highlighting 9% and 10% headline revenue growth respectively, with 8% growth on a constant currency basis.Non-GAAP earnings per share increased 16% in the quarter and 17% for the year, driven by operational efficiencies and margin expansion despite inflationary pressures.The company generated $1.6 billion in free cash flow for fiscal 2026, supporting substantial shareholder returns through over $1 billion in combined share repurchases and dividends, with a notable 72% year-over-year increase in capital returned.

ResMed Unlocks A Bigger Sleep-Health Ecosystem With OURA And Noctrix!

Resmed Inc

ResMed Unlocks A Bigger Sleep-Health Ecosystem With OURA And Noctrix!